KR Choksey is bullish on Supriya Lifescience has recommended buy rating on the stock with a target price of Rs 278 in its research report dated February 17, 2023.

Buy Supriya Lifescience; target of Rs 278: KR Choksey

The margins were impacted due to an increase in labour costs, power and repairs and maintenance.

Supriya Lifescience - Muted Performance On Account Of Multiple Macro Headwinds: KRChoksey

Elecon Engineering Company Ltd, Supriya Lifescience Ltd, Surya Roshni Ltd and Mirza International Ltd are among the other gainers in the BSE’s ‘A’ group today, 17 February 2023.

EKI Energy Services Ltd leads gainers in ‘A’ group

Supriya Lifescience surged 5.26% to Rs 203 on bargain hunting after sliding for five trading sessions.

Supriya Lifescience jumps on bargain hunting

We zoom in on the prospects of Graphite India, as also that of two other stocks — CAMS and Supriya Lifescience

Tech Query: Will the downtrend in Graphite India reverse?

He has over 35+ years of rich functional experience in the manufacturing domain of Bulk Drugs, Intermediate and API with a

Supriya Lifescience appoints Rajeev Kumar Jain as Chief Executive Officer & KMP

Supriya Lifescience Ltd, Incredible Industries Ltd, Viji Finance Ltd and Delphi World Money Ltd are among the other losers in the BSE’s ‘B’ group today, 28 September 2022.

Saksoft Ltd leads losers in ‘B’ group

The Board simultaneously approved the appointment of Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of the Company, who will be joining on October 3, 2022.

Supriya Lifescience stock tumbles as CEO resigns

निवेश से पहले समझें कंपनी का कारोबार | #KYC में मैनेजमेंट से जानें ग्रोथ स्ट्रैटेजी | आज#KnowYourCompany में @SumitResearch बात करेंगे #Supriya Lifescience के Chairman & MD, Satish Wagh और Whole Time Director, Saloni Wagh से |  


Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.

#supriyalifescience  #cnbcawaazlive  #cnbcawaazlive  #aajkatajakhabar  #businessnewslive  #stockmarketlive  #sharemarketlive 

cnbc awaaz live,cnbc awaaz live streaming,cnbc awaaz live hindi,cnbc awaaz,live cnbc awaaz,cnbc,cnbc live,stock market cnbc awaaz,final trade cnbc awwaz live,final trade cnbc bazaar,cnbc awaaz stock pick,cnbc final trade,cnbc awaaz share market,cnbc awaaz intraday picks,cnbc final trade live,cnbc awaaz budget 2022 live,stock market cnbc awaaz, cnbc awaaz live,cnbc,share bazaar live, n18oc_business



CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

KYC में Supriya Lifescience का Management, Q1 और Business Outlook पर विस्तार से बातचीत | CNBC Awaaz

KR Choksey recommended accumulate rating on Supriya Lifescience with a target price of Rs 410 in its research report dated August 18, 2022.

Accumulate Supriya Lifescience; target of Rs 410: KR Choksey

Supriya Lifescience Q1 Review - Improving Capabilities Towards Sustainable Growth: KRChoksey